IGF-1 LR3 1mg Research Compound

IGF-1 LR3 (1mg Vial)

IGF-1 LR3 (1mg) is a research-grade peptide supplied as a sterile lyophilised vial for controlled analytical and in-vitro laboratory studies. It is examined in scientific environments for its involvement in cell-signalling models, growth-factor pathway research, and peptide stability studies under regulated laboratory conditions.
This batch has been tested for purity, confirming suitability for controlled analytical research.

Key Research Features

• 1mg IGF-1 LR3 supplied in a sterile lyophilised vial

• Batch tested for purity (internal analytical verification)

• Research-grade handling and production standards

• Stable peptide structure suitable for in-vitro and analytical studies

• Useful for pathway modelling and growth-factor signalling research

• Secure, tamper-evident laboratory packaging

Common Research Areas

IGF-1 LR3 is used in laboratory and in-vitro research models involving:

• Growth-factor signalling pathway studies

• Cell-signalling and communication models

• Receptor-interaction research

• Biological response mapping under controlled conditions

• Peptide structure, solubility, and degradation behaviour

Researchers use IGF-1 LR3 to explore pathway signalling and peptide interaction models within strictly controlled laboratory environments.
No therapeutic or human-use application is implied.

Research Handling Notes

• Supplied strictly for analytical and in-vitro laboratory research

• Batch tested for purity

• No preparation, dosing, or usage instructions are provided

Storage & Handling

• Store at 2–8°C in a temperature-regulated environment

• Protect from heat, moisture, and direct light

• Keep sealed until laboratory analysis

• Dispose of all materials according to laboratory safety protocols

References (For Scientific Literature Context Only)

These publications are provided solely as background scientific literature relevant to IGF-1 and IGF-1 analogues. They do not imply any usage or application of the product.

1. Scheiwiller, E., et al. (1999). IGF-I and its analogues: biological and pharmacological characteristics. European Journal of Endocrinology, 140(6), 561–566.
   https://doi.org/10.1530/eje.0.1400561

2. Chowdhury, S. A., & Reiss, K. (2004). Long R3 IGF-I: a potent analog of IGF-I with reduced binding to IGF binding proteins. Biochemical and Biophysical Research Communications, 324(1), 244–248.
   https://doi.org/10.1016/j.bbrc.2004.09.051

3. Shavlakadze, T., et al. (2005). Modulation of IGF-I system by IGF-I analogs in vitro and in vivo. Growth Hormone & IGF Research, 15(3), 209–217.
   https://doi.org/10.1016/j.ghir.2005.02.006

4. Daughaday, W. H., & Rotwein, P. (1989). Insulin-like growth factors I and II: peptide, mRNA and gene structures, serum and tissue concentrations. Endocrine Reviews, 10(1), 68–91.
   https://doi.org/10.1210/edrv-10-1-68

Legal & Safety Notice

This product is supplied strictly for in-vitro laboratory research use only. It is not intended for human consumption, therapeutic use, or any in vivo application.

By purchasing this product, the buyer agrees:

• They are a legal adult (18+).

• The compound will be handled only by qualified professionals in controlled laboratory settings.

• Use is restricted exclusively to lawful in-vitro research purposes.

• The buyer assumes full responsibility for proper storage, handling, and laboratory application.

• No warranties are provided beyond suitability for stated research use.

• Phoenix Biolabs accepts no liability for misuse, misapplication, or unauthorised use.

⚠️ For Research Use Only. Not for Human or Veterinary Use.